Literature DB >> 21507737

Melanoma--the pieces of the puzzle finally start coming together! Preface.

Alan Spatz1, Alexander M M Eggermont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21507737      PMCID： PMC5528283          DOI： 10.1016/j.molonc.2011.03.005

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


× No keyword cloud information.
  19 in total

Review 1.  Reducing the effects of lead-time bias, length bias and over-detection in evaluating screening mammography: a censored bivariate data approach.

Authors:  Jonathan D Mahnken; Wenyaw Chan; Daniel H Freeman; Jean L Freeman
Journal:  Stat Methods Med Res       Date:  2008-04-29       Impact factor: 3.021

2.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

3.  Resistance to BRAF inhibition in melanomas.

Authors:  David B Solit; Neal Rosen
Journal:  N Engl J Med       Date:  2011-02-24       Impact factor: 91.245

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

Authors:  Marna G Bouwhuis; Stefan Suciu; Alessandro Testori; Wim H Kruit; François Salès; Poulam Patel; Cornelis J Punt; Mario Santinami; Alain Spatz; Timo L M Ten Hagen; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

7.  Axillary lymph node metastasis in breast cancer: prognostic indicator or lead-time bias?

Authors:  I Mittra
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 8.  Mutant BRAF melanomas--dependence and resistance.

Authors:  Poulikos I Poulikakos; Neal Rosen
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

9.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Authors:  K H T Paraiso; I V Fedorenko; L P Cantini; A C Munko; M Hall; V K Sondak; J L Messina; K T Flaherty; K S M Smalley
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

10.  Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias?

Authors:  Teh-Ia Huo; Yi-Hsiang Huang; Jen-Huei Chiang; Jaw-Ching Wu; Pui-Ching Lee; Chin-Wen Chi; Shou-Dong Lee
Journal:  Scand J Gastroenterol       Date:  2007-04       Impact factor: 2.423
View more
  1 in total

1.  Melanoma--the pieces of the puzzle finally start coming together! Preface.

Authors:  Alan Spatz; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2011-04-03       Impact factor: 6.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.